The CUIDA Chagas Project: towards the elimination of congenital transmission of Chagas disease in Bolivia, Brazil, Colombia, and Paraguay

Sousa, Andréa Silvestre de; Vermeij, Debbie; Parra-Henao, Gabriel; Lesmo, Vidalia; Fernández, Evelin Fortún; Aruni, José Jorge Chura; Mendes, Fernanda de Souza Nogueira Sardinha; Bohorquez, Laura C.; Luquetti, Alejandro O.

doi:10.1590/0037-8682-0171-2021

Cited by 7 publications

(1 citation statement)

References 10 publications

(23 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since the early 1990s, the countries afflicted by CD, with the support and leadership of the Pan American Health Organization (PAHO), have taken steps to lessen CD's impact on population health, 2,3 resulting in significant advances such as a substantial reduction in the number of new cases of domestic vector transmission, prenatal monitoring, and the implementation of universal screening for blood and organ donors, among other initiatives.…”

Section: Introductionmentioning

confidence: 99%

Mother‐to‐child Chagas disease transmission: The challenge of detection and prevention in areas without the risk of vectorial transmission

Gil‐Antuñano

Gold

Abril

et al. 2023

Intl J Gynecology & Obste

View full text Add to dashboard Cite

Chagas disease (CD) is caused by the parasite Trypanosoma cruzi. Although it is endemic in many Latin American (LA) countries, mother‐to‐child transmission has caused it to expand to other countries and continents. In places where vector transmission is controlled or absent, the epidemiological importance of T. cruzi transmission of the infected mother to her child during pregnancy or childbirth (i.e., perinatal CD) increases. In countries where CD is not endemic, CD screening should be performed in pregnant or fertile women who are native to LA countries or whose mothers are native to LA countries. Diagnosis is established by detecting anti–T. cruzi IgG antibodies in a serum or plasma sample. Antiparasitic treatment cannot be offered during pregnancy, and since the majority of infected newborns are asymptomatic at birth, a diagnosis is made by direct observation or concentration (microhematocrit) or by using molecular testing techniques. Once the infected child receives a diagnosis, it is essential to offer treatment (benznidazole/nifurtimox) as soon as possible, with good tolerance and effectiveness in the first year of life. Even if the diagnosis is negative at birth, the newborn must be followed up for at least the first 9 months of life.

show abstract

Section: Introductionmentioning

confidence: 99%